By Fineline Cube 
Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars collaboration, granting Organon commercialization rights for Pyzchiva (ustekinumab biosimilar) in the Canadian market, with a planned launch in 2026.
Partnership Expansion Details
| Component | Detail |
|---|---|
| Parties | Samsung Biologics (CDMO) + Organon (Commercial partner) |
| New Product | Pyzchiva (ustekinumab biosimilar) |
| Territory | Canada |
| Commercial Rights | Exclusive to Organon |
| Expected Launch | 2026 |
| Existing Portfolio | 5 biosimilars across multiple therapeutic areas |
Existing Biosimilars Portfolio
The expanded agreement builds upon Samsung Biologics’ established partnership with Organon, which already includes five marketed biosimilars:
- Hadlima (adalimumab) – TNF inhibitor for autoimmune diseases
- Brenzys (etanercept) – TNF inhibitor for rheumatoid arthritis and psoriasis
- Renflexis (infliximab) – TNF inhibitor for inflammatory conditions
- Aybintio (bevacizumab) – Anti-angiogenic for oncology indications
- Ontruzant (trastuzumab) – HER2-targeted therapy for breast cancer
The addition of Pyzchiva (ustekinumab biosimilar) represents the sixth product in the collaboration, targeting the IL-12/23 pathway for psoriasis, psoriatic arthritis, and Crohn’s disease.
Strategic Rationale
- Market Opportunity: The Canadian biosimilars market is projected to reach CAD $1.2 billion by 2027, with ustekinumab representing a high-value target due to its premium pricing and patent expiry timeline.
- Organon’s Commercial Infrastructure: Leveraging Organon’s established presence in Canada’s women’s health and biosimilars markets to accelerate Pyzchiva adoption.
- Samsung Biologics’ Manufacturing Scale: Utilizing Samsung’s world-class CDMO capabilities, including its 256,000L bioreactor capacity, to ensure reliable supply.
- Portfolio Diversification: Expanding beyond TNF inhibitors into the IL-12/23 pathway strengthens the partnership’s therapeutic area coverage.
Competitive Landscape
- Ustekinumab Market: Original product Stelara generated US$7.4 billion globally in 2025, with Canadian sales estimated at CAD $280 million.
- Biosimilar Competition: Pyzchiva will compete with other ustekinumab biosimilars from Alvotech, Fresenius Kabi, and Celltrion, but benefits from Samsung Biologics’ manufacturing expertise and Organon’s commercial experience.
- Regulatory Pathway: Health Canada’s progressive biosimilars approval framework supports rapid market entry following successful comparability studies.
Financial Implications
While specific financial terms were not disclosed, industry analysts estimate the Canadian ustekinumab biosimilar market could generate CAD $150-200 million annually by 2028, with Organon capturing 25-30% market share based on its existing biosimilars performance.
Forward-Looking Statements
This brief contains forward-looking statements regarding product launches, market opportunities, and partnership outcomes. Actual results may differ due to regulatory approvals, competitive dynamics, and market adoption rates.-Fineline Info & Tech